TC 6683
Alternative Names: AZD 1446; TC-6683Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Targacept
- Developer AstraZeneca
- Class Antidementias; Small molecules
- Mechanism of Action Alpha4 beta2 nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder
Most Recent Events
- 05 Feb 2020 Attenua has been acquired and merged into CODA Biotherapeutics
- 02 Aug 2016 Catalyst Biosciences enters into a definitive agreement with Attenua for the divestiture of its neuronal nicotinic receptors
- 30 Jun 2013 Discontinued - Phase-I for Alzheimer's disease in Japan and Sweden (PO, Liquid)